AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 231 min read$ABBV

AbbVie Inc. (ABBV) Wins FDA Nod for Skyrizi SC Induction in Crohn’s

AbbVie received FDA approval for a subcutaneous induction regimen of Skyrizi for Crohn’s disease, allowing at-home initiation and maintenance. This expands the drug’s existing approvals and supports AbbVie’s immunology portfolio.

Original reporting
tradingview.com
Published Oct 23, 2026, 7:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 23, 2026, 7:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AbbVie Inc. (ABBV) Wins FDA Nod for Skyrizi SC Induction in Crohn’s — source image
Source · tradingview.com
Decision brief

The 30-second read

$ABBVBullishHigh
01

Why it matters

The FDA nod is a primary regulatory event that can drive short‑term price appreciation and long‑term revenue growth.

02

Market read

First report of FDA approval for Skyrizi's new indication; material news for AbbVie and the biotech sector.

03

What to watch

Potential manufacturing scale-up challenges and competition from biosimilars.

Relevance 7/10Novelty 9/10Timing: today

Background

AbbVie's Skyrizi already has approval for maintenance; this adds an at‑home induction option for Crohn's patients.

Company-level read

Ticker impact

$ABBVBullishHigh confidence
Context

AbbVie received FDA approval for a subcutaneous induction regimen of Skyrizi for Crohn's disease.

Expected impact

likely upside as investors price in new market opportunity

Evidence & confidence

Regulatory clearance is a concrete catalyst; market typically reacts positively to label expansions.

Market effects

Sector

strengthens the broader IBD/autoimmune drug sector as competitors may face heightened scrutiny.

Regional

U.S. biotech stocks may see modest gains following the approval.

Global

Adds to global pipeline momentum for biologics targeting inflammatory diseases.

Counterpoint

What could challenge this read

If payer coverage is delayed, the sales impact could be muted despite approval.

Key entities

  • Company
    AbbVie Inc.

    Pharmaceutical company receiving FDA approval.

  • Drug
    Skyrizi

    AbbVie's IL‑23 inhibitor now approved for subcutaneous induction in Crohn's disease.

Read at source← All news

StoryFDA approves subcutaneous induction regimen of AbbVie’s SKYRIZI for Crohn’s disease

Also covered by

5 outlets

Related articles

OCT 23
$ABBVHigh

U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SK

AbbVie's SKYRIZI (risankizumab-rzaa) received FDA approval for a subcutaneous induction regimen in adults with moderately to severely active Crohn's disease. The approval is based on positive Phase 3 AFFIRM trial results, showing superior clinical remission and endoscopic response at week 12 compared to placebo, especially in treatment-naïve patients. The subcutaneous form allows for at-home administration using an on-body injector.

gurufocus.com2 min
OCT 23
$ABBVHigh

FDA approves subcutaneous induction regimen for AbbVie’s Skyrizi

AbbVie (ABBV) received FDA approval for a subcutaneous induction regimen of Skyrizi for Crohn's disease. The regimen involves 720 mg doses at weeks 0, 2, 4, and 8, with maintenance doses every 8 weeks. The approval is based on Phase 3 trial results showing 56% clinical remission vs. 30% for placebo. The FDA also updated prescribing info to remove mandatory TB testing. Skyrizi is approved for several autoimmune diseases.

investing.com2 min
OCT 23
$ABBVHigh

U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's Disease

AbbVie's SKYRIZI® (risankizumab-rzaa) received FDA approval for a subcutaneous induction regimen in adults with moderately to severely active Crohn's disease. The approval is based on Phase 3 AFFIRM trial results showing superior clinical remission and endoscopic response at week 12 compared to placebo, with no new safety risks identified. The subcutaneous option allows for at-home treatment using an on-body injector.

news.abbvie.com3 min
OCT 23
$ABBVHigh

FDA approves AbbVie’s Crohn’s drug for home shots; 74% of patients with no prior advanced-treatment failure were in remission at week 12.

FDA approved AbbVie's subcutaneous SKYRIZI for Crohn's disease, allowing home administration. Phase 3 AFFIRM study showed 74% remission in patients without prior advanced therapy failure at week 12. Safety profile consistent with known risks. FDA also updated TB testing guidelines for SKYRIZI. According to AbbVie, this approval provides greater treatment flexibility. SKYRIZI is an IL-23 inhibitor approved for several immune-mediated diseases.

stocktitan.net2 min
OCT 23
$ABBVMedAI 8/10

AbbVie’s skin disease drug posts Phase III win as market competition heats up

AbbVie's lutikizumab met primary endpoints in Phase III INTREPID trial for hidradenitis suppurativa (HS), reducing flares and skin pain. 31.4% of patients achieved HiSCR75 vs. 23.4% on placebo. Analysts noted response rates were lower than expected, but AbbVie highlights the drug's potential. Competitors include Novartis' Cosentyx and UCB's Bimzelx. HS market projected to grow to $7.8bn by 2034, according to GlobalData.

clinicaltrialsarena.com2 min